S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:EOLS

Evolus (EOLS) Stock Price, News & Analysis

$14.00
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$13.92
$14.37
50-Day Range
$11.63
$14.91
52-Week Range
$7.07
$15.43
Volume
706,671 shs
Average Volume
669,788 shs
Market Capitalization
$811.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.60

Evolus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
47.1% Upside
$20.60 Price Target
Short Interest
Bearish
10.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.46mentions of Evolus in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$744,574 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.51) to ($0.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.75 out of 5 stars

Medical Sector

270th out of 938 stocks

Pharmaceutical Preparations Industry

121st out of 423 stocks

EOLS stock logo

About Evolus Stock (NASDAQ:EOLS)

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS Stock Price History

EOLS Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Evolus Inc.
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Latest News for Evolus Stock (NASDAQ:EOLS)
Evolus (EOLS) Receives a Buy from Barclays
Recap: Evolus Q4 Earnings
Evolus Q4 2023 Earnings Preview
See More Headlines
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/23/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
273
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.60
High Stock Price Target
$27.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+47.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-61,690,000.00
Pretax Margin
-30.44%

Debt

Sales & Book Value

Annual Sales
$202.09 million
Book Value
($0.36) per share

Miscellaneous

Free Float
54,815,000
Market Cap
$811.16 million
Optionable
Optionable
Beta
1.45
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. David MoatazediMr. David Moatazedi (Age 46)
    President, CEO & Director
    Comp: $1.27M
  • Ms. Sandra Beaver (Age 46)
    Chief Financial Officer
    Comp: $372.23k
  • Dr. Rui Avelar C.CFP (Age 62)
    Dip.SportMed, M.D., Chief Medical Officer and Head of Research & Development
    Comp: $682.03k
  • Mr. Nareg Sagherian
    Head of Global Investor Relations & Corporate Communications
  • Mr. Jeffrey J. Plumer
    General Counsel
  • Mr. Kurt Knab
    Vice President of Sales
  • Ms. Tomoko Yamagishi-Dressler
    Chief Marketing Officer
  • Ms. Jessica Novak
    Senior Vice President of Human Resources

EOLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Evolus stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings
or view top-rated stocks.

What is Evolus' stock price target for 2024?

3 brokers have issued 12 month price objectives for Evolus' shares. Their EOLS share price targets range from $16.00 to $27.00. On average, they anticipate the company's share price to reach $20.60 in the next year. This suggests a possible upside of 47.1% from the stock's current price.
View analysts price targets for EOLS
or view top-rated stocks among Wall Street analysts.

How have EOLS shares performed in 2024?

Evolus' stock was trading at $10.53 at the start of the year. Since then, EOLS stock has increased by 33.0% and is now trading at $14.00.
View the best growth stocks for 2024 here
.

When is Evolus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EOLS earnings forecast
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) posted its earnings results on Tuesday, March, 23rd. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The company earned $20.58 million during the quarter, compared to analyst estimates of $20.60 million. Evolus had a negative trailing twelve-month return on equity of 507.42% and a negative net margin of 30.52%.
Read the conference call transcript
.

What guidance has Evolus issued on next quarter's earnings?

Evolus updated its FY 2024 earnings guidance on Friday, March, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $261.2 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?
When did Evolus IPO?

Evolus (EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Who are Evolus' major shareholders?

Evolus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.32%), Perceptive Advisors LLC (6.93%), Vanguard Group Inc. (5.15%), Vanguard Group Inc. (5.15%), Nantahala Capital Management LLC (5.09%) and Great Point Partners LLC (3.50%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Karah Herdman Parschauer, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar, Sandra Beaver and Vikram Malik.
View institutional ownership trends
.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EOLS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners